Topics:

Oncology and Hematology News and Journal Articles

FDA Approves Ramucirumab for Second-Line Treatment of mCRC

The FDA has approved ramucirumab, a human VEGFR2 antagonist in combination with FOLFIRI for second-line treatment of patients with metastatic colorectal cancer.

Recent Content

Advocacy is about making sure that our lawmakers enact the best healthcare policies for our patients. Just as we have a duty to our patients in the clinic, we also have a duty to advocate for laws that benefit patients’ health.

Trabectedin failed to improve progression-free survival outcomes compared to doxorubicin as first-line therapy for advanced/metastatic soft-tissue sarcoma.

The multi-targeted TKI lenvatinib showed promise in a phase II trial of patients with advanced, radioiodine-refractory, differentiated thyroid cancer.

This slide show features some of the top highlights from the 2015 American Association for Cancer Research (AACR) Annual Meeting.

A 30-year-old man who recently underwent induction chemotherapy for bone marrow transplant is admitted with neutropenia and right lower-quadrant abdominal pain. What is your diagnosis?

Understanding treatment-induced neurotoxicity can be difficult when treating patients with central nervous system (CNS) malignancies.

A multi-gene panel test provides better diagnostic yield compared with a limited BRCA1/2 genetic test for patients at risk for hereditary breast cancer.

By clicking Accept, you agree to become a member of the UBM Medica Community.